Paradoxical role of hepatocyte growth factor in ischemic stroke: stroke risk/stroke recovery

Table 9 The concentration of HGF level in stroke patients with and without vascular risk factors

Stroke patients (N = 100)	HGF Concentration (ng/ml)		U test	P value
Stroke patients (N = 100)	X ± SD	Range	U test	P value
Hypertensive (N = 67)	0.59 ± 0.14	0.4–0.85	6.24	< 0.001*
Non-hypertensive (N = 33)	0.37 ± 0.17	0.15–0.82	6.24	< 0.001*
Diabetic (N = 67)	0.62 ± 0.17	0.23–0.85	6.24	< 0.001*
Non-diabetics (N = 33)	0.40 ± 0.11	0.15–0.54	6.24	< 0.001*
Smoker (N = 32)	0.72 ± 0.07	0.60–0.85	7.83	< 0.001*
Non-smoker (N = 68)	0.42 ± 0.12	0.15–0.82	7.83	< 0.001*
Dyslipidemic (N = 48)	0.61 ± 0.18	0.43 ± 0.12	5.07	< 0.001*
Non-dyslipidemic (N = 52)	0.17–0.83	0.15–0.85	5.07	< 0.001*
Obese (N = 59)	0.60 ± 0.15	0.23–0.83	5.90	< 0.001*
Non-obese (N = 41)	0.39 ± 0.13	0.15–0.82	5.90	< 0.001*

X mean, SD standard deviation, U Mann–Whitney U test, *highly significant, HGF hepatocyte growth factor